Digital Assets Report


Like this article?

Sign up to our free newsletter

Euronext and Biotech Bourse launch first quarterly biotech sector barometer

Related Topics

Euronext has published its first Biotech Barometer, a quarterly tool that offers an insight into major trends in biotechnology companies, which includes only companies offering diagnostics and therapies listed on Euronext markets.

Designed in partnership with Biotech Bourse, the barometer shows performance indicators, investor interest and market sentiment specifically for this sector.
Biotech is a key sector for Euronext: between 2012 and 2016 the number of biotech companies listed on its markets rose from 12 to 45, with a market capitalisation of nearly EUR12 billion. The Biotech Barometer is designed to showcase this fast-moving sector. In addition to providing information to biotech companies – both listed and unlisted – it will help CEOs assess their momentum against a broader benchmark and give ordinary investors a simple guide to tracking market trends.
The quarterly publication is underpinned by data and innovative tools developed by Biotech Bourse and Euronext’s Post-Listing Services. The Biotech Barometer includes trends in market statistics—prices, volumes and indexes; a market sentiment indicator; institutional investor interest (number, capital invested, region of origin); and key performance indicators for the biotech industry: companies’ cash positions, calls on the market, treatment areas and published clinical results.
According to the first Biotech Barometer, although market sentiment remained cautious, Euronext and Biotech Bourse found that interest in biotech stocks rallied in Q4 2016. December was the sector’s fourth best month in 2016 with trading in the 45 Euronext-listed biotech stocks covered by the Barometer generating over EUR46 million daily.
Some 140 new institutional investors bought shares in the 45 biotech companies, producing capital inflows of over EUR600 million. While 75 per cent of these investors were based in Europe, 20 per cent were in North America and 5 per cent were in Asia.
The rate of calls on the market increased: the 45 Biotech companies listed on Euronext markets raised EUR214 million in Q4, up 75.2 per cent over the previous quarter. In total they raised over EUR1 billion in 2016 (primary and secondary issues combined).
At year-end 2016, some 330 institutional investors were identified as holding positions in the 45 biotech companies, with combined holdings of over EUR3 billion and two-thirds of that total from Europe.

Like this article? Sign up to our free newsletter

Most Popular

Further Reading